Monoclonal antibodies as disease modifying therapy in multiple sclerosis

Area of Science:

• Neuroimmunology
• Pharmacology
• Clinical Neurology

Background:

• Multiple sclerosis (MS) is a central nervous system demyelinating disease.
• Early treatments like beta-interferons and glatiramer acetate were nonspecific.
• Recent research prioritizes targeted therapies for MS.

Purpose of the Study:

• To review the efficacy and safety of monoclonal antibodies (mAbs) for multiple sclerosis.
• To discuss mAbs approved or in late-stage clinical trials for MS.
• To analyze mAbs found ineffective or harmful in MS patients.

Main Methods:

• Literature review of approved and investigational monoclonal antibodies for MS.
• Analysis of clinical trial data focusing on efficacy and safety profiles.
• Inclusion of studies on mAbs that failed or caused adverse effects in MS.

Main Results:

• Several monoclonal antibodies have demonstrated significant efficacy in MS treatment.
• Monoclonal antibodies offer targeted mechanisms of action compared to older therapies.
• Some monoclonal antibodies have shown limited efficacy or adverse events in MS.

Conclusions:

• Monoclonal antibodies represent a significant advancement in multiple sclerosis therapeutics.
• Careful evaluation of efficacy and safety is crucial for selecting appropriate mAbs.
• Understanding the outcomes of all studied mAbs, including failures, informs future MS drug development.